Feb 25, 2020 ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Exercise of Common Stock Warrants
Feb 11, 2020 ProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Investor Conference
Jan 29, 2020 ProMIS Neurosciences Data for Alzheimer’s Disease Program Targeting Tau Accepted for Presentation at Tau2020
Jan 8, 2020 ProMIS Neurosciences issues Chairman’s Update detailing positive outlook for Alzheimer’s disease therapy, pipeline in 2020
Dec 10, 2019 ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news